178 related articles for article (PubMed ID: 37352151)
1. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.
Ichimiya T; Kazama T; Ishigami K; Yokoyama Y; Hayashi Y; Takahashi S; Itoi T; Nakase H
PLoS One; 2023; 18(6):e0286415. PubMed ID: 37352151
[TBL] [Abstract][Full Text] [Related]
2. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
[TBL] [Abstract][Full Text] [Related]
3. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
[TBL] [Abstract][Full Text] [Related]
5. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease.
Kawamura T; Yamamura T; Nakamura M; Maeda K; Sawada T; Ishikawa E; Iida T; Mizutani Y; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M
Inflamm Bowel Dis; 2023 Feb; 29(2):245-253. PubMed ID: 35436345
[TBL] [Abstract][Full Text] [Related]
8. Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease.
Abe I; Shiga H; Chiba H; Miyazawa T; Oomori S; Shimoyama Y; Moroi R; Kuroha M; Kakuta Y; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Sep; 37(9):1741-1748. PubMed ID: 35641439
[TBL] [Abstract][Full Text] [Related]
9. Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis.
Yamazato M; Yanai S; Oizumi T; Eizuka M; Yamada S; Toya Y; Uesugi N; Sugai T; Matsumoto T
World J Clin Cases; 2023 Nov; 11(32):7753-7760. PubMed ID: 38073694
[TBL] [Abstract][Full Text] [Related]
10. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
12. Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms.
Hayashi T; Kitamura K; Usami M; Miyazawa M; Nishitani M; Dejima A; Yamamoto M; Kawase S; Funaki M; Orita N; Nakagawa H; Morita K; Iida N; Seki A; Nio K; Kido H; Takayama H; Takeuchi Y; Yamada S; Takatori H; Shimada M; Saito H; Yamamoto D; Toyama T; Yamashita T
Inflamm Intest Dis; 2023 Dec; 8(4):133-142. PubMed ID: 38115911
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis.
Matsumoto S; Mashima H
Crohns Colitis 360; 2022 Oct; 4(4):otac039. PubMed ID: 36778513
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
15. Serum Leucine-Rich α
Kawamoto A; Takenaka K; Hibiya S; Ohtsuka K; Okamoto R; Watanabe M
Clin Gastroenterol Hepatol; 2022 May; 20(5):e1196-e1200. PubMed ID: 34216822
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.
Yasutomi E; Inokuchi T; Hiraoka S; Takei K; Igawa S; Yamamoto S; Ohmori M; Oka S; Yamasaki Y; Kinugasa H; Takahara M; Harada K; Furukawa M; Itoshima K; Okada K; Otsuka F; Tanaka T; Mitsuhashi T; Kato J; Okada H
Sci Rep; 2021 May; 11(1):11086. PubMed ID: 34045529
[TBL] [Abstract][Full Text] [Related]
17. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
[TBL] [Abstract][Full Text] [Related]
18. Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease.
Takenaka K; Kitazume Y; Kawamoto A; Fujii T; Udagawa Y; Wanatabe R; Shimizu H; Hibiya S; Nagahori M; Ohtsuka K; Sato H; Hirakawa A; Watanabe M; Okamoto R
Am J Gastroenterol; 2023 Jun; 118(6):1028-1035. PubMed ID: 36571769
[TBL] [Abstract][Full Text] [Related]
19. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients.
Cannatelli R; Bazarova A; Zardo D; Nardone OM; Shivaji U; Smith SCL; Gkoutos G; Ricci C; Gui XS; Ghosh S; Iacucci M
Inflamm Bowel Dis; 2021 Apr; 27(5):647-654. PubMed ID: 32592477
[TBL] [Abstract][Full Text] [Related]
20. Significance of Serum Leucine-rich Alpha-2 Glycoprotein as a Diagnostic Marker in Pediatric Inflammatory Bowel Disease.
Yoshimura S; Okata Y; Ooi M; Horinouchi T; Iwabuchi S; Kameoka Y; Watanabe A; Kondo A; Uemura K; Tomioka Y; Samejima Y; Nakai Y; Nozu K; Kodama Y; Bitoh Y
Kobe J Med Sci; 2024 Jan; 69(4):E122-E128. PubMed ID: 38379274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
